Literature DB >> 17173920

Estrogen therapy and brain muscarinic receptor density in healthy females: a SPET study.

Ray Norbury1, Michael J Travis, Kjell Erlandsson, Wendy Waddington, Peter J Ell, Declan G M Murphy.   

Abstract

Estrogen Therapy (ET) may protect against age-related cognitive decline and neuropsychiatric disorders (e.g. Alzheimer's disease). The biological basis for this putative neuroprotective effect is not fully understood, but may include modulation of cholinergic systems. Cholinergic dysfunction has been implicated in age-related memory impairment and Alzheimer's disease. However, to date no one has investigated the effect of long-term ET on brain cholinergic muscarinic receptor aging, and related this to cognitive function. We used Single Photon Emission Tomography (SPET) and (R,R)[(123)I]-I-QNB, a novel ligand with high affinity for m(1)/m(4) muscarinic receptors, to examine the effect of long-term ET and age on brain m(1)/m(4) receptors in healthy females. We included 10 younger premenopausal subjects and 22 postmenopausal women; 11 long-term ET users (all treated following surgical menopause) and 11 ET never-users (surgical menopause, n=2). Also, verbal memory and executive function was assessed in all postmenopausal subjects. Compared to young women, postmenopausal women (ET users and never-users combined) had significantly lower muscarinic receptor density in all brain regions examined. ET users also had higher muscarinic receptor density than ET never-users in all the brain regions, and this reached statistical significance in left striatum and hippocampus, lateral frontal cortex and thalamus. Moreover, in ET users, (R,R)[(123)I]-I-QNB binding in left hippocampus and temporal cortex was significantly positively correlated with plasma estradiol levels. We also found evidence for improved executive function in ET users as compared to ET never-users. However, there was no significant relationship between receptor binding and cognitive function within any of the groups. In healthy postmenopausal women use of long-term ET is associated with reduced age-related differences in muscarinic receptor binding, and this may be related to serum estradiol levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17173920     DOI: 10.1016/j.yhbeh.2006.10.007

Source DB:  PubMed          Journal:  Horm Behav        ISSN: 0018-506X            Impact factor:   3.587


  21 in total

Review 1.  Hormone therapy and cognitive function.

Authors:  Pauline M Maki; Erin Sundermann
Journal:  Hum Reprod Update       Date:  2009-05-25       Impact factor: 15.610

Review 2.  Estrogen-cholinergic interactions: Implications for cognitive aging.

Authors:  Paul Newhouse; Julie Dumas
Journal:  Horm Behav       Date:  2015-07-14       Impact factor: 3.587

3.  Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity.

Authors:  Yolanda R Smith; Luvina Bowen; Tiffany M Love; Alison Berent-Spillson; Kirk A Frey; Carol C Persad; Nancy K Reame; Robert A Koeppe; Jon-Kar Zubieta
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

4.  Chronic (3-Weeks) Treatment of Estrogen (17β-Estradiol) Enhances Working and Reference Memory in Ovariectomized Rats: Role of Acetylcholine.

Authors:  Gulay Uzum; Nesrin Bahcekapili; Abdulkerim Kasim Baltaci; Rasim Mogulkoc; Yusuf Ziya Ziylan
Journal:  Neurochem Res       Date:  2016-02-15       Impact factor: 3.996

5.  Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.

Authors:  Morgane Thomsen; Jürgen Wess; Brian S Fulton; Anders Fink-Jensen; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

Review 6.  Mechanisms of action of estrogen in the brain: insights from human neuroimaging and psychopharmacologic studies.

Authors:  Pauline M Maki; Julie Dumas
Journal:  Semin Reprod Med       Date:  2009-04-28       Impact factor: 1.303

7.  Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women.

Authors:  Paul Newhouse; Kimberly Albert; Robert Astur; Julia Johnson; Magdalena Naylor; Julie Dumas
Journal:  Neuropsychopharmacology       Date:  2013-07-19       Impact factor: 7.853

8.  Thalamo-Basal Ganglia connectivity in postmenopausal women receiving estrogen therapy.

Authors:  Heather A Kenna; Natalie L Rasgon; Cheri Geist; Gary Small; Daniel Silverman
Journal:  Neurochem Res       Date:  2008-06-06       Impact factor: 3.996

9.  Estradiol interacts with the cholinergic system to affect verbal memory in postmenopausal women: evidence for the critical period hypothesis.

Authors:  Julie Dumas; Catherine Hancur-Bucci; Magdalena Naylor; Cynthia Sites; Paul Newhouse
Journal:  Horm Behav       Date:  2007-10-26       Impact factor: 3.587

Review 10.  Neuroprotective effects of estrogen therapy for cognitive and neurobiological profiles of monkey models of menopause.

Authors:  Mary Lou Voytko; Gregory Paul Tinkler; Carole Browne; Joseph R Tobin
Journal:  Am J Primatol       Date:  2009-09       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.